Adoptive immunotherapy using OK-432-activated mononuclear cells (OK-MCs) offers cell-mediated and cytokine-mediated pathways for antitumor activity. The effectiveness of direct intratumoral administration of OK-MCs via a catheter/reservoir system was studied in patients with malignant brain tumors. Seventeen patients, 12 with malignant glioma, four with metastatic adenocarcinoma, and one with primary sarcoma of the brain, were treated by OK-MC therapy (1.0 to 11.2 × 10 7 cells/person) between June 1989 and April 1999. The OK-MC therapy was given to patients with tumors progressing despite previous cytoreductive surgery, radiation, or chemotherapy. Adverse effects seen after the therapy were fever in 10 patients, seizure in two patients, and hypotension in one patient. Evaluation by computed tomography or magnetic resonance imaging revealed that seven patients showed no change including three with minor response, and 10 showed progressive disease. Adoptive immunotherapy using OK-MC was safe and well tolerated, but the therapeutic potential is limited.
Introduction
Malignant brain tumors can be treated by various intensive methods including surgery, radiation, and chemotherapy, but no therapy is curative. 2, 12) Immunological treatments are of intense interest, such as``lymphokine-activated killer (LAK) cells'' obtained by the incubation of peripheral blood mononuclear cells (PBMCs) with interleukin (IL)-2 which can kill a wide variety of autologous and allogenic tumor cells in vitro. 4, 17) Several clinical trials with intratumoral infusion of LAK cells and IL-2 through an Ommaya's catheter/reservoir system have been reported. 1, 10, 13, 15, 22) However, the clinical results are controversial, with some workers concluding that immunotherapy with LAK cells is ineffective, whereas others have suggested the strategy is promising and safe for patients with malignant brain tumor. 1) OK-432 is a heat and penicillin-treated lyophilized powder of the Su-strain of Streptococcus pyogenes A3, and has been used as an immunostimulant to induce or augment antitumor activities in patients with cancers. 20) PBMCs incubated with OK-432 for 24 hours acquire cytolytic activity against fresh human tumor cells both in vitro and in vivo. Such PBMCs are called OK-432-activated mononuclear cells (OK-MCs). OK-MCs produce several cytokines, such as interferon (IFN) a, IFN g, tumor necrosis factor, IL-1, and IL-2. 3, [5] [6] [7] [8] Furthermore, the cytocidal activity of OK-MCs to human glioma cells is mediated at least in part through the Fas and FasL system. The FasL expressed on OK-MCs can induce apoptosis in Fas-expressing human glioblastoma cells in vitro. 18) The present study included 17 patients with malignant brain tumors treated by surgery and intratumoral infusion of OK-MCs, to evaluate the effect of this therapy by computed tomography (CT) or magnetic resonance (MR) imaging, neurological status, and clinical outcome. 
I. Patients
This study involved 17 patients, 15 males and two females aged 25 to 76 years (mean 54.1 years), with advanced symptomatic disease from supratentorial malignant brain tumor (Table 1) . Twelve patients had malignant astrocytoma, four had metastatic adenocarcinoma, and one had primary sarcoma of the brain. All diagnoses were established by stereotactic needle biopsy or surgical resection. OK-MC therapy was applied to patients with progressing tumors despite cytoreductive surgery, radiation, or chemotherapy. Informed consent was obtained from all patients or guardians.
II. Preparation of OK-MCs
Peripheral blood was obtained from each patient and separated by gradient centrifugation using Lymphocyte Separation Medium (Organon Technika Co., Durham, N.C., U.S.A). [5] [6] [7] OK-432 (Chugai Pharmaceutical Co., Tokyo) is a lyophilized preparation of Streptococcus pyogenes A3 killed by penicillin and H 2 O 2 . One Klinische Einheit (KE) of OK-432 is equivalent to 0.1 mg of lyophilized preparation. PBMCs were suspended at 2 × 10 5 cells/ml in serum-free RPMI 1640 containing 0.25 KE of OK-432 and cultured for 24 hours at 379 C in a humidified atmosphere of 5% CO 2 in air. OK-MCs were then collected by centrifugation and washed with phosphate buffered saline. The supernatants were passed through a 0.22-mm Millipore filter (Japan Millipore Ltd., Tokyo) and stored at -209 C until use.
III. Adoptive immunotherapy
The patients underwent cranial surgery in which generous tumor resections were performed. A catheter with an Ommaya's reservoir (Baxter Healthcare Co., Deerfield, Ill., U.S.A.) was placed and directed into the tumor bed for postoperative infusion of OK-MCs. After surgery, all patients except for two with metastatic adenocarcinoma were treated with a total of 45 to 60 Gy focal radiation and concomitant systemic chemotherapy. OK-MC therapy was then given at intervals of 1 to 16 months (mean 7 months) after the adjuvant therapy (radiation/chemotherapy). Glucocorticoid administration was limited during adoptive immunotherapy except in patients who exhibited progressive neurological aggravation due to massive perifocal cerebral edema. Tumor response was evaluated by the neuroimaging criteria proposed by the Committee of Brain Tumor Registry of Japan, graded as: complete response (CR), disappearance of the tumor for at least 4 weeks; partial response (PR), greater than 50% reduction in tumor size continuing for more than 4 weeks; no change (NC); and progressive disease (PD). The tumor size was measured using the greatest width and length. Neurological status was evaluated as improved, no change, and worsened simultaneously with the CT or MR imaging evaluation.
IV. IFN g activity in the tumor cavity fluid
Cytokine activity in the fluid of the tumor cavity was examined in five patients (Cases 1-5). Fluid samples were obtained through the reservoir every week after adoptive immunotherapy. IFN g activity was determined by radioimmunoassay using specific monoclonal antibodies against human IFN g. 5, 6, 8) 
Results
The 17 patients received a total of 53 courses of the adoptive immunotherapy using OK-MCs. Patients received from 1 to 10 courses of OK-MC treatment (Table 2) .
Cytotoxicity assays using the standard 4-hour chromium-51 assays and subpopulations of peripheral blood T cells were performed at the beginning of our study. Cytotoxicity data revealed that the activity against natural killer-sensitive K562 cells was increased throughout the treatment courses. In contrast, subpopulations of T cells in the peripheral blood of patients showed no definite changes during the treatment course (data not shown). IFN g activity in the tumor cavity fluid was measured to evaluate the cytokine activity of the OK-MC therapy in the No patient died as a result of the immunotherapy. The adverse effects of the therapy were relatively minor and transient. The side effects were fever in 10 patients, seizure in two patients, and hypotension in one patient (Table 2) . Transient hypotension was induced immediately after the second adoptive immunotherapy in Case 3, possibly due to the leakage of OK-MCs into the ventricular system due to rupture of the tumor cavity wall into the lateral ventricle. Follow-up CT with injection of contrast medium into the tumor cavity through the Ommaya's reservoir revealed a marked connection of the tumor cavity with the cerebral ventricle. Therefore, further immunotherapy with OK-MCs was not performed in this patient.
CT or MR imaging evaluation revealed that no patient with CR or PR after the therapy, seven with NC including three minor response, and 10 with PD ( Table 2 ). Fifteen of the 17 patients have died of disease progression to date, during follow-up periods ranging from 2 months to 75 months. The median survival times are 18.1 months after initial OK-MC therapy. The overall median survival time was 16.3 months in patients with glioblastoma. T. Hirotsu et al.
Illustrative Cases
Case 17: A 61-year-old male suffered from headache and presented with left hemiparesis. MR imaging demonstrated an enhanced tumor in the right putamen. Stereotactic needle biopsy confirmed anaplastic astrocytoma. Conventional radiation and chemotherapy were performed, followed by two courses of OK-MC therapy. Follow-up MR imaging after the therapy demonstrated a clear reduction in the enhanced area of the tumor, but no change in tumor size, evaluated as NC (Fig. 2) . Case 6: A 57-year-old male underwent total removal of a metastatic adenocarcinoma in the right frontal lobe. The postoperative course was uneventful, but the tumor recurred within 3 months. He was readmitted and again underwent total removal of the tumor. After the second craniotomy, two courses of OK-MC therapy were performed. Follow-up CT demonstrated ring-like enhancement of the tumor cavity, which may suggest tumor recurrence or immunological reaction to the therapy. However, he did not show any neurological symptoms or systemic inflammatory reactions. Sequential CT demonstrated a remarkable reduction of the enhanced area that eventually disappeared. He was discharged with complete clinical recovery. Follow-up CT after 72 months showed no tumor recurrence (Fig. 3) .
Discussion
Adequate numbers of lymphocytes with the potential for developing cytotoxic activity can be obtained by automated leukophoresis of the peripheral blood of patients with tumors. Human IL-2 or OK-432 can activate these cells as immunomodulatory agents with toxicity against human tumor cells. Clinical trials have involved the intrathecal administration of LAK cells or tumor-sensitized lymphocytes. OK-432 is one of the biological response modifiers. OK-MCs showed cytolytic activity against both natural killer cell-resistant cultured cells and the tumor cells in vivo. 6, 11) Kinetic analysis of the cytolytic activity demonstrated the maximum level by 48 hours of culture at a low concentration of 0.02-0.05 KE/ml of OK-432. 6, 7) However, LAK cells need a longer time of incubation for 3 to 5 days and large amounts of IL-2 to acquire cytotoxic activity. The early induction of killing activity in OK-MCs is favorable for clinical applications because of the lower risk of bacterial contamination. Local administration of OK-MCs for patients with gastric cancer 6, 8) and head and neck cancer 11) observed a remarkable antitumor effect in two of 10 cases of gastric cancer and six of 17 cases of head OK-MC Therapy for Malignant Brain Tumors and neck cancer. Histological examination suggested that the antitumor effect might be mainly due to the cytokines produced by OK-MCs rather than the OK-MCs themselves. 6, 8, 11) The present study used local administration of OK-MCs through the Ommaya's catheter/reservoir system for 17 patients with malignant brain tumor. Evaluation by CT or MR imaging revealed NC in seven patients and PD in 10. These results do not indicate that the present treatment is a most promising therapy for malignant brain tumors. However, the overall median survival of patients with glioblastoma after OK-MC therapy was 16.3 months, in contrast to 11.8 months in those without OK-MC therapy in our clinic. Although the reasons for the difference are not clear, OK-MC therapy may induce a prolonged dormant phase in patients with glioblastoma and thus increase survival time.
The primary side effects of OK-MC therapy were transient fever and seizure. Such side effects are also seen in the IL-2 and LAK therapy. Cerebral edema and neurological deterioration occurred in all patients treated with a relatively high dose of IL-2 and a much larger number of LAK cells administered locally. Our Case 9 suffered from massive cerebral edema after the first administration of OK-MC, but the patient tolerated the incident well and recovered. These results suggest that there is little difference in side effects between OK-MC and LAK therapy and the patients can tolerate the therapy.
Our previous studies found that the cytotoxic activity of OK-MCs to human malignant gliomas was mediated at least in part through the Fas and FasL system. FasL is a 40 kd type II transmembrane protein and induces apoptosis by binding to the receptor Fas. 14) Fas is a member of the tumor necrosis factor receptor superfamily. Fas is expressed in some malignant gliomas and anti-Fas antibodies or FasL can induce apoptosis in glioma cell lines. 16, 18, 19) FasL acts as a cytotoxic effector molecule against Fasexpressing malignant tumor cells. Several studies including ours have demonstrated that Fas is expressed on the surface of malignant glioma cells and that recombinant human FasL can induce apoptosis in glioma cell lines in vitro. 9, 21) We speculate that OK-MCs could induce apoptosis in human malignant brain tumors. However, further studies are required to establish more effective immunotherapy methods for malignant brain tumors.
